ELUTIA INC. (ELUT) stock intrinsic value fair value estimate & owner earnings analysis

Elutia develops biologic matrix products used in reconstructive surgery. In October 2025 it sold its cardiac device envelope business (EluPro and CanGaroo) to Boston Scientific for up to $88.0 million in cash, and in 2023 it sold its bone-graft business to Berkeley Biologics. What remains is a small operation: SimpliDerm, a human dermal matrix used in soft-tissue reconstruction ($9.1 million of 2025 sales), and a cardiovascular repair line of ProxiCor, VasCure and Tyke ($3.2 million). Total 2025 sales were $12.3 million, down 15% from 2024, and the company is putting its money into NXT-41 and NXT-41x, next-generation matrices that are still in development. Owner earnings, meaning the cash the business generates after stock compensation, working-capital swings and equipment spending, have been negative every year we can measure. Per share they were about -$4.43 in 2020 (a partial-year share count after the IPO), -$2.12 in 2021, -$2.00 in 2022, -$1.25 in 2023, -$1.08 in 2024 and -$0.95 in 2025. The 2025 net profit of $53.4 million came from the one-time gain on selling the cardiac business, not from operations, so we do not treat it as earning power. Operating cash use was $16.3 million in the first half of 2026, and cash fell from $36.4 million at the end of 2025 to $19.9 million at June 30, 2026. Gross profit on current products was only $6.6 million in 2025, against $15.1 million of general and administrative cost, $5.8 million of selling cost, $4.2 million of research and $8.5 million of litigation cost. What the company holds against that burn: $19.9 million of cash, $8.0 million held in escrow from the Boston Scientific sale (due for release about twelve months after the October 2025 closing, and reducible if the buyer makes valid claims), and a recorded litigation reserve of $11.2 million at year-end 2025 ($6.8 million for FiberCel and $4.4 million for viable bone matrix claims, both retained from the bone-graft business). Insurance is exhausted for FiberCel, so that part falls on the company. It also owes Ligand at least $4.4 million a year in revenue-interest payments through May 2027. Netting cash, escrow and the litigation reserve gives roughly $16.7 million, or about $0.38 per share on about 44.2 million shares, before any further losses. Bear case, $0.00 per share: the first-half 2026 burn continues, the remaining cash and escrow (about $27.9 million together) are used up in roughly ten months, and further funding would come only by issuing shares at a heavy discount. Nothing evidenced turns that spending into earnings, so the shares are worth nothing beyond what is spent. Base case, $0.00 per share: the median path is the same. Current products earn far less than the company spends, and no future earnings can be counted for NXT-41 or NXT-41x because neither has been cleared or sold. The Berkeley earn-out (10% of that buyer's sales of the sold products, up to $20 million over five years) has paid nothing so far, so it is left out. At the current burn rate, the roughly $16.7 million of net assets lasts about six months, which is why we credit no residual value. Bull case, $0.21 per share: management stops the burn now, having already sold two businesses (in 2023 and 2025), and loses one more quarter at the second-quarter 2026 pace (net loss of $7.6 million). That leaves about $9.1 million, or about $0.21 per share. We do not credit new product success or a sale price for the remaining lines because neither is evidenced. Because the shares have little value beyond cash that is being spent, the margin-of-safety price is very low, and it applies only once the burn has been brought under control. What would make this analysis wrong: a cleared, commercially successful NXT-41 product or a substantial Berkeley earn-out payment would add value we have excluded, and smaller-than-expected litigation payments or a larger escrow release would increase what is left. Notes on judgement: stock compensation was subtracted as a real cost. Litigation costs were left in owner earnings as ongoing cash costs, not stripped out as working capital. The company reports it has enough cash for at least a year after its 10-K was issued. No prior analysis existed for comparison.